Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. MorphoSys AG
  6. News
  7. Summary
    MOR   DE0006632003

MORPHOSYS AG

(MOR)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 07/29 04:19:38 am
46.02 EUR   +1.93%
02:20aMORPHOSYS : Gets a Neutral rating from JP Morgan
MD
07/28MORPHOSYS : Reports Second Quarter and First Half 2021 Results
PU
07/28PRESS RELEASE : MorphoSys AG Reports Second -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE: MorphoSys to Acquire Constellation -2-

06/02/2021 | 07:26am EDT
MorphoSys will host a conference call and webcast to discuss the transaction on June 2, 2021 at 2:00 p.m. CEST, or 8:00 
a.m. EDT. The webcast and accompanying slides can be accessed in the Media and Investors section, under Conferences, of 
MorphoSys' website at http://www.morphosys.com or at http://morphosys-constellation-royaltypharma.com/. After the call, 
a slide-synchronized audio replay of the conference will be available at the same location. 
The live call is also available at: 
Germany: +49 69 201 744 220 
For UK residents: +44 203 009 2470 
For US residents: +1 877 423 0830 
Participant PIN: 78217587# 
Please dial in 10 minutes before the beginning of the conference. 
About MorphoSys 
MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development 
and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its 
leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates 
and has created antibodies which are developed by partners in different areas of unmet medical need. In 2017, Tremfya^ 
(R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the 
treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory 
approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of the company's 
proprietary product Monjuvi^(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of 
lymphoma. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys 
US Inc., has more than 600 employees. More information at www.morphosys.com or www.morphosys-us.com. 
Monjuvi^(R) is a registered trademark of MorphoSys AG. 
Tremfya^(R) is a registered trademark of Janssen Biotech, Inc. 
About Constellation 
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that 
selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a 
deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune 
microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving 
development of the BET inhibitor pelabresib for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 
for the treatment of advanced malignancies. The Company is also applying its broad research and development 
capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable 
pipeline of innovative small-molecule product candidates. 
About Royalty Pharma 
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation 
across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and 
not-for-profits through small- and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty 
Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of 
many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both 
directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new 
product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original 
innovators. Royalty Pharma's current portfolio includes royalties on more than 45 commercial products, including AbbVie 
and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's Trodelvy, Merck's Januvia, Novartis' 
Promacta, and Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. 
Additional Information and Where to Find it 
The tender offer described in this communication has not yet commenced. This communication is for informational 
purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Constellation 
Pharmaceuticals Inc. ("Constellation"), nor is it a substitute for any tender offer materials that MorphoSys AG 
("MorphoSys"), or Constellation will file with the SEC. A solicitation and an offer to buy shares of Constellation will 
be made only pursuant to an offer to purchase and related materials that MorphoSys intends to file with the SEC. At the 
time the tender offer is commenced, MorphoSys will file a Tender Offer Statement on Schedule TO with the SEC, and 
Constellation will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the 
tender offer. CONSTELLATION'S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING 
AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/ 
RECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY 
DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain 
other tender offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of 
Constellation at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement will be 
made available for free at the SEC's website at www.sec.gov. Additional copies may be obtained for free by contacting 
MorphoSys or Constellation. Free copies of these materials and certain other offering documents will be made available 
by MorphoSys by mail to MorphoSys AG., Semmelweisstrasse 7, 82152 Planegg, Germany, attention: Investor Relations, by 
phone at 49 (0)89 / 899 27 179, or by directing requests for such materials to the information agent for the offer, 
which will be named in the Tender Offer Statement. Copies of the documents filed with the SEC by Constellation will be 
available free of charge under the "Investors" section of Constellation's internet website at https:// 
ir.constellationpharma.com/investor-relations. 
In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as 
well as the Solicitation/Recommendation Statement, Constellation and MorphoSys file periodic reports and other 
information with the SEC. MorphoSys' and Constellation's filings with the SEC are also available for free to the public 
from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov. 
Forward Looking Statements 
This communication contains forward-looking statements, within the meaning of the Private Securities Litigation Reform 
Act of 1995, related to MorphoSys, Constellation and the acquisition of Constellation by MorphoSys (the "Transaction") 
that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are 
statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or 
current expectation of the companies' and members of their senior management team. Forward-looking statements include, 
without limitation, statements regarding the Transaction and related matters, prospective performance and 
opportunities, post-closing operations and the outlook for the companies' businesses, including, without limitation, 
the ability of MorphoSys to advance Constellation's product pipeline, including pelabresib (CPI-0610) and CPI-0209, 
FSI-174 and FSI-189; regulatory approval of pelabresib (CPI-0610) and CPI-0209 on a timely basis; the anticipated 
timing of clinical data; the possibility of unfavorable results from clinical trials; filings and approvals relating to 
the Transaction; the expected timing of the completion of the Transaction; the expected plans for financing the 
Transaction (including the strategic partnership and financing collaboration with Royalty Pharma); the ability to 
complete the Transaction considering the various closing conditions; difficulties or unanticipated expenses in 
connection with integrating the companies; and any assumptions underlying any of the foregoing. Investors are cautioned 
that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties 
and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially 
from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause 
the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to 
the timing of the tender offer and merger; uncertainties as to how many of Constellation's stockholders will tender 
their stock in the offer; the possibility that competing offers will be made; the possibility that various closing 
conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay 
or refuse to grant approval for the consummation of the Transaction; the effects of the Transaction on relationships 
with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of 
FDA approvals or actions, if any; the impact of competitive products and pricing; other business effects, including the 
effects of industry, economic or political conditions outside of the companies' control; Transaction costs; actual or 
contingent liabilities; and other risks and uncertainties detailed from time to time in the parties' periodic reports 
filed with the U.S. Securities and Exchange Commission (the "SEC"), including current reports on Form 8-K, quarterly 
reports on Form 10-Q, annual reports on Form 10-K, Form 20-F, and Form 6-K as well as the Schedule 14D-9 to be filed by 

(MORE TO FOLLOW) Dow Jones Newswires

June 02, 2021 07:25 ET (11:25 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 0.50% 118.55 Delayed Quote.10.64%
ASTELLAS PHARMA INC. -0.37% 1905 End-of-day quote.19.51%
CONSTELLATION PHARMACEUTICALS, INC. 0.06% 33.99 Delayed Quote.18.02%
DJ INDUSTRIAL -0.36% 34930.93 Delayed Quote.14.83%
MORPHOSYS AG 0.58% 45.4 Delayed Quote.-51.88%
NASDAQ COMP. 0.70% 14762.584267 Real-time Quote.15.15%
ROYALTY PHARMA PLC -1.71% 38.53 Delayed Quote.-23.02%
All news about MORPHOSYS AG
02:20aMORPHOSYS : Gets a Neutral rating from JP Morgan
MD
07/28MORPHOSYS : Reports Second Quarter and First Half 2021 Results
PU
07/28PRESS RELEASE : MorphoSys AG Reports Second -2-
DJ
07/28PRESS RELEASE : MorphoSys AG Reports Second -3-
DJ
07/28MORPHOSYS : Reports Second Quarter and First Half 2021 Results
EQ
07/28PRESS RELEASE : MorphoSys AG Reports Second Quarter and First Half 2021 Results
DJ
07/27MORPHOSYS : Commerzbank Downgrades MorphoSys to Hold Rating From Buy
MT
07/26EUROPE : European stocks ease from peaks, Prosus hits 1-year low
RE
07/26European ADRs Move Higher in Monday Trading
MT
07/26AD HOC : MorphoSys AG to update financial guidance for 2021 and reduce financial..
PU
More news
Financials
Sales 2021 170 M 201 M 201 M
Net income 2021 -239 M -284 M -284 M
Net cash 2021 601 M 713 M 713 M
P/E ratio 2021 -6,97x
Yield 2021 -
Capitalization 1 540 M 1 818 M 1 825 M
EV / Sales 2021 5,53x
EV / Sales 2022 3,53x
Nbr of Employees 609
Free-Float 99,6%
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | MarketScreener
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 45,15 €
Average target price 105,07 €
Spread / Average Target 133%
EPS Revisions
Managers and Directors
Jean-Paul Kress CEO & Chairman-Management Board
Sung H. Lee Chief Financial Officer
Marc Cluzel Chairman-Supervisory Board
Malte Peters Chief Research & Development Officer
Roland Wandeler Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
MORPHOSYS AG-51.88%1 818
MODERNA, INC.234.37%131 902
LONZA GROUP AG20.01%55 520
IQVIA HOLDINGS INC.36.95%46 608
CELLTRION, INC.-27.16%31 131
SEAGEN INC.-16.58%26 209